Amylyx Pharmaceuticals In... (AMLX)
3.29
-0.20 (-5.73%)
At close: Jan 28, 2025, 1:49 PM
Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
It is also developing AMX0035 for other neurodegenerative diseases.
The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 384 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 43 Thorndike Street Cambridge, Massachusetts United States | |
| Website | https://amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer & Director |
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer & Director |
| Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel |
| James M. Frates M.B.A. | Chief Financial Officer |
| Chris Aiello | Head of Canada & GM |
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer |
| Linda A. Arsenault | Chief Human Resources Officer |
| Lindsey Allen | Head of Investor Relations & Communications |
| Shauna Horvath | Head of Global Marketing |
| Tom Holmes | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | SCHEDULE 13G | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 424B5 | Filing |
| Jan 10, 2025 | 424B5 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |